?AIM: To analyze the efficacy of intravitreal injection of Conbercept in the treatment of diabetes macular edema with 6+PRN regimen. ?METHODS: Retrospective analysis of clinical data of 144 DME patients (214 eyes) admitted to the hospital for concomitant therapy from January 2019 to January 2022. Randomly divided into two groups: 68 cases (102 eyes) in the 3+PRN group were treated with intravitreal injection of Conbercept using 3+PRN; 76 cases (112 eyes) in the 6+PRN group were treated with intravitreal injection of Conbercept using 6+PRN. Follow up for 12 months and observe the visual acuity, CMT, number of injections, and complications of the two groups of patients. ?RESULTS: At the end of 12 months after completing the medication injection, the visual acuity of patients in the 6+PRN group was significantly better than that in the 3+PRN group, with a statistically significant difference (t=3.25, P=0.016); The CMT of patients in the 6+PRN group was significantly lower than that in the 3+PRN group, and the difference was statistically significant (t=4.36, P=0.009); However, the average number of drug injections between the two groups of patients was comparable, and the difference was not statistically significant (t=3.55, P=0.126). ?CONCLUSIONS: The Conbercept 6+PRN regimen better reduces macular edema and improves vision, but does not increase the medical burden and risk for patients.